While no clinical trial to date has specifically targeted fatigue , r and omized controlled trials , systematic review s , and meta-analyses indicate that treatment modalities studied in the context of other fibromyalgia symptoms could also improve fatigue .
Fatigue is a disabling , multifaceted symptom that is highly prevalent and stubbornly persistent .
Although fatigue is a frequent complaint among patients with fibromyalgia , it has not received the same attention as pain .
Reasons for this include lack of st and ardized nomenclature to communicate about fatigue , lack of evidence -based guidelines for fatigue assessment , and a deficiency in effective treatment strategies .
Fatigue does not occur in isolation ; rather , it is present concurrently in varying severity with other fibromyalgia symptoms such as chronic widespread pain , unrefreshing sleep , anxiety , depression , cognitive difficulties , and so on .
Survey-based and preliminary mechanistic studies indicate that multiple symptoms feed into fatigue and it may be associated with a variety of physiological mechanisms .
Toward Development of a Fibromyalgia Responder Index and Disease Activity Score: OMERACT Module Update
Following development of the core domain set for fibromyalgia ( FM ) in Outcome Measures in Rheumatology Clinical Trials ( OMERACT ) meetings 7 to 9 , the FM working group has progressed toward the development of an FM responder index and a disease activity score based on these domains , utilizing outcome indices of these domains from archived r and omized clinical trials in FM . Possible clinical domains that could be included in a responder index and disease activity score include pain , fatigue , sleep disturbance , cognitive dysfunction , mood disturbance , tenderness , stiffness , and functional impairment . Outcome measures for these domains demonstrate good to adequate psychometric properties , although measures of cognitive dysfunction need to be further developed . The approach used in the development of responder indices and disease activity scores for rheumatoid arthritis and ankylosing spondylitis represents heuristic models for our work , but FM is challenging in that there is no clear algorithm of treatment that defines disease activity based on treatment decisions , nor are there objective markers that define thresholds of severity or response to treatment . The process of developing c and i date dichotomous responder definitions and continuous quantitative disease activity measures is described , along with participant discussion s from OMERACT 10 . Final results of this work will be published in a separate report pending completion of analyses
While no clinical trial to date has specifically targeted fatigue , r and omized controlled trials , systematic review s , and meta-analyses indicate that treatment modalities studied in the context of other fibromyalgia symptoms could also improve fatigue .
Fatigue is a disabling , multifaceted symptom that is highly prevalent and stubbornly persistent .
Although fatigue is a frequent complaint among patients with fibromyalgia , it has not received the same attention as pain .
Reasons for this include lack of st and ardized nomenclature to communicate about fatigue , lack of evidence -based guidelines for fatigue assessment , and a deficiency in effective treatment strategies .
Fatigue does not occur in isolation ; rather , it is present concurrently in varying severity with other fibromyalgia symptoms such as chronic widespread pain , unrefreshing sleep , anxiety , depression , cognitive difficulties , and so on .
Survey-based and preliminary mechanistic studies indicate that multiple symptoms feed into fatigue and it may be associated with a variety of physiological mechanisms .